The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 ...
Featured at this year’s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and ...
The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007 included a safety run-in period and a randomized expansion phase, which enrolled patients ...
Boster Bio today announced expanded access to its human VEGF ELISA kits, designed to support accurate and reproducible quantification of vascular endothelial growth factor (VEGF) in human serum. The ...
Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...
A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results